Last reviewed · How we verify
OnabotulinumtoxinA (Vistabel®)
OnabotulinumtoxinA works by temporarily paralyzing muscles to treat various conditions.
OnabotulinumtoxinA works by temporarily paralyzing muscles to treat various conditions. Used for Blepharospasm, Cervical dystonia, Focal spasticity.
At a glance
| Generic name | OnabotulinumtoxinA (Vistabel®) |
|---|---|
| Also known as | "BOTOX® Cosmetic", "Botulinum toxin type A (900 kiloDalton)" |
| Sponsor | Merz Pharmaceuticals GmbH |
| Drug class | botulinum toxin |
| Target | acetylcholine release |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It does this by blocking the release of acetylcholine, a neurotransmitter that signals muscle contraction. This leads to a reduction in muscle spasms and contractions, providing relief for conditions such as blepharospasm and cervical dystonia.
Approved indications
- Blepharospasm
- Cervical dystonia
- Focal spasticity
- Hemifacial spasm
- Severe primary axillary hyperhidrosis
- Strabismus
- Upper limb spasticity
Common side effects
- Eyelid ptosis
- Diplopia
- Headache
- Injection site pain
- Facial asymmetry
Key clinical trials
- A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections (PHASE4)
- Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides (PHASE4)
- Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
- Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines (PHASE4)
- Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds (PHASE4)
- Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines (PHASE4)
- NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnabotulinumtoxinA (Vistabel®) CI brief — competitive landscape report
- OnabotulinumtoxinA (Vistabel®) updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI